UnitedHealthcare SCS/DRG Coverage Update

Coverage Criteria for SCS and DRG Stimulation

Medically necessary — SCS

Covered when performed according to FDA labeled indications and InterQual CP criteria

Medically necessary SCS indications: SCS is proven and medically necessary for complex regional pain syndrome (CRPS), painful diabetic neuropathy, and failed back surgery syndrome when performed per FDA-labeled indications, contraindications, warnings, precautions and InterQual CP: Procedures, Spinal Cord Stimulator (SCS) Insertion.

See InterQual for detailed medical necessity criteria.

Not medically necessary — SCS

Not medically necessary due to insufficient evidence

SCS unproven indications: Chronic intractable back pain without prior spine surgery; refractory angina pectoris are considered unproven and not medically necessary for implanted electrical spinal cord stimulators.

Evidence summaries indicate insufficient peer-reviewed evidence for these indications.

DRG stimulation — coverage stance

Covered and not covered DRG indications

Medically necessary DRG indication: DRG stimulation is proven and medically necessary for complex regional pain syndrome (CRPS I and II) when performed per FDA-labeled indications, contraindications, warnings, precautions and InterQual CP: Procedures, Spinal Cord Stimulator (SCS) Insertion.

Refer to InterQual for specific clinical criteria.

DRG unproven indications: DRG stimulation is unproven and not medically necessary for all other conditions outside the FDA-labeled CRPS indication due to insufficient evidence of efficacy.

Systematic reviews and evidence assessments report low-quality or limited evidence for other neuropathic and focal pain etiologies.

Replacement battery/generator

Replacement battery/generator: Coverage of a replacement battery/generator for a previously implanted electrical stimulator is appropriate when the existing device is malfunctioning, cannot be repaired, and is no longer under warranty.

Candidate selection / typical coverage criteria

Evidence and typical selection criteria reported in the literature (excerpted):

Typical candidate selection for DRG stimulation: Patients with focal neuropathic or refractory focal pain (e.g., CRPS, causalgia, pelvic/groin pain, post-surgical inguinal pain, selected peripheral neuropathies, discogenic low back pain) who have failed conservative therapies and demonstrate a successful trial (commonly ≥50% pain relief).trial success often defined as ≥50% pain reduction

Based on RCTs, cohorts, and systematic reviews; evidence quality often low

Revised coverage rationale (summary)

Policy changes indicate updated lists of proven and medically necessary conditions and updated stance on DRG stimulation.

Policy revision summary: Revised list of proven and medically necessary conditions; DRG stimulation is stated as proven and medically necessary for treating complex regional pain syndrome when performed according to FDA labeled indications, contraindications, warnings, and precautions.

Detailed criteria sets are located in other parts of the full policy.

This policy distinguishes between indications with sufficient evidence and those considered unproven. Implanted spinal cord stimulation (SCS) and dorsal root ganglion (DRG) stimulation are covered when performed according to FDA‑labeled indications and InterQual® CP clinical criteria. Specifically, SCS is listed as proven and medically necessary for complex regional pain syndrome (CRPS), painful diabetic neuropathy, and failed back surgery syndrome. DRG stimulation is listed as proven and medically necessary for CRPS I and II. Conversely, interventions for indications not identified as proven (for example, chronic intractable back pain without prior spine surgery and DRG/SCS use outside the FDA‑labeled CRPS indication) are described as unproven and not medically necessary due to insufficient evidence.

The evidence base for DRG stimulation supports effectiveness for CRPS type I and II, where DRG is stated as proven and medically necessary when performed per FDA labeling and InterQual criteria. For other neuropathic etiologies (cancer‑related neuropathic pain, postherpetic neuralgia, diabetic peripheral neuropathy outside the FDA indication, central neuropathic pain from MS, stroke, ischemia, or amputation), the literature is sparse and of very low quality; systematic reviews and cohort series report unknown or inconsistent effectiveness and call for larger, well‑designed comparative studies. Consequently, DRG stimulation is considered not medically necessary for all conditions outside the FDA‑labeled CRPS indication.

The 2022 VA/DoD Clinical Practice Guideline for low back pain recommended against the use of SCS for patients with low back pain. This guideline finding is cited in the evidence discussion to indicate limited support for primary axial low back pain; however, the UnitedHealthcare policy applies its own coverage determinations and references InterQual criteria for specific medical necessity requirements.

Implanted electrical spinal cord stimulators are explicitly listed as not medically necessary for chronic intractable back pain without prior spine surgery due to insufficient evidence of efficacy. Evidence reviews (including the 2025 Hayes brief) identified no randomized controlled trials evaluating certain SCS technologies for primary chronic back pain without prior surgery and found guideline and position statement support primarily for post‑surgical persistent back pain rather than nonoperative axial back pain.

Systematic reviews of spinal cord and DRG stimulation for low back pain report limited or no benefit at clinically meaningful follow‑up. A 2023 Cochrane review found no improvement in function, pain, or quality of life at six months for SCS in low back pain, and DRG literature is characterized by small, heterogeneous, low‑quality studies that preclude definitive conclusions. These systematic reviews underpin the policy’s cautious stance and support limiting coverage to indications with stronger evidence (e.g., CRPS, PDN, FBSS).

The VA/DoD 2022 guideline recommendation against SCS for low back pain is reiterated in the policy’s evidence summary to emphasize that independent national guidance does not support SCS for primary low back pain. UnitedHealthcare references these guideline conclusions while retaining its own coverage framework that defers to FDA labeling and InterQual clinical criteria for definitive medical necessity determinations.

Conservative Treatment and Trial Requirements

Failure of conservative therapies prior to trial is commonly required in study populations.

Failure of conservative therapies prior to trial: Most published DRG and SCS study populations include patients who have failed other pharmacologic and nonpharmacologic interventions; a trial stimulation and demonstration of inadequate response to conservative therapies is commonly required prior to permanent implantation.

ASRAPM guidelines recommend trial stimulation and psychosocial screening prior to implant.

Failure of conventional medical management (timing / prior surgery notes)

Failure of conventional medical management: For HF10 therapy (Senza), patients should have residual chronic neuropathic back or leg pain at least six months after back surgery despite conventional medical management prior to consideration of SCS.>= 6 months after back surgery

A successful stimulation trial as part of a multidisciplinary assessment is also recommended.

Provider Actions, Documentation, and Prior Authorization

Prior Authorization

Prior Authorization and Code References

Prior authorization is typically required before SCS or DRG device implantation. Verify plan-specific prior authorization requirements and submit supporting documentation (see documentation callouts below).

Affected codes include CPT 63650, 63655, 63685, 63688 and HCPCS L8679–L8695.
Use InterQual® Procedures, Spinal Cord Stimulator (SCS) Insertion criteria when available to meet medical necessity review.

Note

Trial Stimulation Recommended

A stimulation trial (temporary trial stimulation) is recommended prior to permanent implant for most indications (excluding angina per ASRAPM guidance). Trial results should demonstrate adequate pain relief (commonly ≥50% reduction) and improved function to justify permanent implantation.

Document trial start and end dates, lead placement details, stimulation parameters, and objective pain scores before and after trial.
HF10 (Senza) guidance and other device-specific recommendations still support performing a successful trial prior to permanent implant.

Coding References and Product Codes

Covered CPT Codes (reference list)CPT

63650	Percutaneous implantation of neurostimulator electrode array, epidural.
63655	Laminectomy for implantation of neurostimulator electrodes, plate/paddle, epidural.
63685	Insertion or replacement of spinal neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver.
63688	Revision or removal of implanted spinal neurostimulator pulse generator or receiver, with detachable connection to electrode array

Covered HCPCS/L codes (reference list)HCPCS

L8679	Implantable neurostimulator, pulse generator, any type.
L8680	Implantable neurostimulator electrode, each.
L8682	Implantable neurostimulator radiofrequency receiver.
L8685	Implantable neurostimulator pulse generator, single array, rechargeable, includes extension.
L8686	Implantable neurostimulator pulse generator, single array, nonrechargeable, includes extension.
L8687	Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension.
L8688	Implantable neurostimulator pulse generator, dual array, nonrechargeable, includes extension.
L8695	External recharging system for battery (external) for use with implantable neurostimulator, replacement only

FDA product codes mentionedmixed

LGW	FDA product code referenced for PMA process (SCS-related)
GZB	FDA product code referenced for PMA process (SCS-related)
GZF	FDA product code referenced for 510(k) process (SCS-related)
PMP	FDA product code referenced for DRG stimulation devices

Imaging and Diagnostic Test Requirements

Note

Refractory angina evaluation (study context)

In the refractory angina study context, ischemia was proven by MIBI‑SPECT in 69% of participants — a study detail included for context but not stated as a policy requirement.

This is an observational study detail and does not establish an imaging requirement in the policy.

Note

No explicit imaging requirements described

No explicit imaging requirements for SCS or DRG stimulation are described in this policy excerpt.

Do not assume mandatory imaging beyond documentation of pertinent diagnostic tests unless specified by plan or InterQual.

Documentation Required

Diagnostic test/procedure results required in medical record

Definitions and Key Terms

Replacement battery/generator — definition / coverage condition

DefinitionCoverage of a replacement battery/generator for a previously implanted electrical stimulator is appropriate when the individual's existing battery/generator is malfunctioning, cannot be repaired, and is no longer under warranty.

ContextApplies to previously implanted spinal neurostimulator systems when device replacement is required due to malfunction or end of service life.

Documentation neededMedical record should demonstrate device malfunction, inability to repair, and lack of warranty coverage to support medical necessity.

Trial stimulation — definition and success threshold

DefinitionA temporary stimulation period prior to permanent implant used to assess effectiveness of neurostimulation for the target pain condition.

Common success threshold

Frequency and Quantity Limits

No specific frequency limits provided in this excerpt.

StatementNo specific frequency limits for procedures or therapies are provided in the excerpted policy text.

ImplicationFrequency limits (utilization/frequency of service) are not specified here; refer to full policy or plan-specific tools for any limits.

DocumentationWhen frequency constraints are relevant to coverage, check InterQual or plan-specific prior authorization tools as directed by the policy.

Services Not Covered / Considered Experimental

Not covered (unproven / not medically necessary) indications include: chronic intractable back pain without prior spine surgery; refractory angina pectoris for implanted SCS; and DRG stimulation for indications other than FDA‑labeled CRPS. The policy notes that evidence for DRG in other neuropathic conditions (cancer pain, postherpetic neuralgia, diabetic peripheral neuropathy outside labeled indications, central neuropathic pain) is very low quality or lacking, and that systematic reviews of low back pain report limited or no benefit—supporting the not‑medically‑necessary determinations for these indications.

Background and Evidence Summary

Background: Spinal cord stimulation (SCS) and dorsal root ganglion (DRG) stimulation are implantable neuromodulation therapies used to treat chronic neuropathic and refractory pain. The policy identifies SCS as proven and medically necessary for CRPS, painful diabetic neuropathy, and failed back surgery syndrome, and identifies DRG stimulation as proven for CRPS I and II when performed per FDA labeling and InterQual clinical criteria. Evidence assessments and systematic reviews cited in the policy report positive signals for these select indications but note that the body of evidence for many other pain conditions is small, heterogeneous, and generally low quality, leading to restrictive coverage for non‑labeled uses.

Policy Revision History

2026-02-01policy_revisionLatest

Revised coverage rationale: updated list of proven and medically necessary conditions (changed wording for diabetic neuropathy) and updated DRG stimulation language to state it is proven and medically necessary for treating complex regional pain syndrome when performed per FDA-labeled indications.

2026-02-01policy_revision

Added explicit medical records documentation requirements: the patient record must fully support medical necessity and include relevant history, physical exam, and diagnostic test results; documentation must be legible, maintained, and available upon request.

OpenPayer

Implanted Electrical Stimulator for the Spinal Cord (for Idaho Only)

Coverage Criteria for SCS and DRG Stimulation

Conservative Treatment and Trial Requirements

Provider Actions, Documentation, and Prior Authorization

Coding References and Product Codes

Imaging and Diagnostic Test Requirements

Definitions and Key Terms

Frequency and Quantity Limits

Services Not Covered / Considered Experimental

Background and Evidence Summary

Policy Revision History